HOME >> BIOLOGY >> NEWS
JCI table of contents: Aug. 9, 2007

EDITOR'S PICK: New molecular regulators of hyperthyroidism and goiter

The thyroid gland has an important role in determining how much energy the body burns. Thyroid gland functions are regulated by a hormone known as thyroid-stimulating hormone (TSH). Increased levels of TSH, as well as increased signaling through the receptor for TSH, result in hyperthyroidism (characterized by weight loss because the body increases the amount of energy it burns) and goiter.

Signals downstream of the receptor for TSH had been thought to be mediated mainly by a protein complex known as Gs. But now, a study that appears online on August 9, in advance of publication in the September print issue of the Journal of Clinical Investigation, indicates that in mice Gq/G11-mediated signaling has an essential role in transmitting TSH-induced signals and therefore in regulating thyroid gland function. This makes Gq and G11 potential new targets for the treatment of hyperthyroidism and goiter.

In the study, Stefan Offermanns and colleagues from the University of Heidelberg, Germany, generated mice lacking the alpha-subunits of both Gq and G11 only in cells of the thyroid gland. These mice had reduced thyroid gland function and many had symptoms similar to individuals with hypothyroidism. In addition, the thyroid gland in these mice was unresponsive to the proliferative effects of TSH and a goitrogenic diet. The authors therefore suggest that inhibiting Gq and G11, or the molecules activated downstream of these G proteins, might be of therapeutic benefit for individuals with diseases characterized by increased thyroid gland function and/or growth.

TITLE: Thyrocyte-specific Gq/G11 deficiency impairs thyroid function and prevents goiter development

AUTHOR CONTACT:
Stefan Offermanns
University of Heidelberg, Heidelberg, Germany.
Phone: 49-6221-54-8246; Fax: 49-6221-54-8549; E-mail:

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
9-Aug-2007


Page: 1 2 3 4 5

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: August 1, 2007
3. US Department of Defense awards $1.6 million for implantable biochip research
4. More fish oil, less vegetable oil, better for your health
5. JCI table of contents -- July 26, 2007
6. JCI table of contents: July 19, 2007
7. JCI table of contents: July 12, 2007
8. JCI table of contents: June 21, 2007
9. JCI table of contents: June 14, 2007
10. Food safety begins as vegetables grow
11. Turning the tables in chemistry

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents Aug

(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
(Date:12/19/2014)... 18, 2014 iLab Solutions, the global ... of Siri Bryant as the new Director of Institutional ... Core Implementations. These two new leadership positions were created ... by ensuring that iLab continues to meet the needs ... four years, iLab has been deployed at over 450 ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: